ADMA Biologics Inc (ADMA)vsargenx NV ADR (ARGX)
ADMA
ADMA Biologics Inc
$13.19
+0.38%
HEALTHCARE · Cap: $2.93B
ARGX
argenx NV ADR
$981.33
+0.38%
HEALTHCARE · Cap: $58.31B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 1039% more annual revenue ($5.92B vs $519.15M). ADMA leads profitability with a 35.1% profit margin vs 31.7%. ADMA trades at a lower P/E of 17.1x. ARGX earns a higher WallStSmart Score of 73/100 (B).
ADMA
Buy64
out of 100
Grade: C+
ARGX
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADMA.
Margin of Safety
+67.3%
Fair Value
$2552.01
Current Price
$981.33
$1570.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 42 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Earnings expanding 46.7% YoY
Every $100 of equity generates 33 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Safe zone — low bankruptcy risk
Areas to Watch
No major concerns identified
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 182.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ADMA
The strongest argument for ADMA centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 35.1% and operating margin at 44.9%.
Bull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bear Case : ADMA
No major red flags identified for ADMA, but monitor valuation.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ADMA profiles as a mature stock while ARGX is a growth play — different risk/reward profiles.
ADMA carries more volatility with a beta of 0.66 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 64/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADMA Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Visit Website →argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?